ASCO-GI 2024 – Novartis Tightens Its Grip On The Radiopharmaceutical Space
Lutathera yields a 72% reduction in the risk of progression or death in first-line GEP-NETs trial.
Lutathera yields a 72% reduction in the risk of progression or death in first-line GEP-NETs trial.